Unresectable Hepatocellular Carcinoma

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer

First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant